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The nuclear factor of activated T cells (NFAT) transcription factor is implicated in expression of the cytokine
interleukin-2 (IL-2). Binding sites for NFAT are located in the IL-2 promoter. Furthermore, pharmacological
studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression. However,
targeted disruption of the NFAT1 and NFAT2 genes in mice does not cause decreased IL-2 secretion. The role
of NFAT in IL-2 gene expression is therefore unclear. Here we report the construction of a dominant-negative
NFAT mutant (dnNFAT) that selectively inhibits NFAT-mediated gene expression. The inhibitory effect of
dnNFAT is mediated by suppression of activation-induced nuclear translocation of NFAT. Expression of
dnNFAT in cultured T cells caused inhibition of IL-2 promoter activity and decreased expression of IL-2
protein. Similarly, expression of dnNFAT in transgenic mice also caused decreased IL-2 gene expression. These
data demonstrate that NFAT is a critical component of the signaling pathway that regulates IL-2 expression.
The nuclear factor of activated T cells (NFAT) group of
proteins were first characterized as transcription factors that
bind to the interleukin-2 (IL-2) promoter (13, 22, 40, 42). The
NFAT transcription factor consists of two components: a cy-
toplasmic Rel domain protein (NFAT family member) and a
nuclear component consisting of activating protein 1 (AP-1)
transcription factors (Fos- and Jun-related proteins) and prob-
ably other transcription factors (reviewed in reference 38). Four
members of the NFAT group have been identified: NFAT1
(NFATp/NFATc2), NFAT2 (NFATc/NFATc1), NFAT3, and
NFAT4 (NFATx/NFATc3) (17, 19, 27, 29, 31). NFAT1 and
NFAT2 are expressed predominantly in lymphoid tissues (thy-
mocytes, T cells, B cells, mast cells and NK cells), but NFAT2
is also expressed in muscle cells. NFAT4 is expressed mainly in
the thymus and NFAT3 is expressed primarily in nonlymphoid
tissues. The major NFAT proteins expressed in peripheral T
cells that produce IL-2 correspond to the isoforms NFAT1 and
NFAT2.
While NFAT is thought to be important for IL-2 gene ex-
pression, recent studies demonstrate that NFAT may also con-
tribute to the expression of other cytokines, including IL-3,
IL-4, IL-5, granulocyte-macrophage colony-stimulating factor,
and tumor necrosis factor (8, 10, 12, 28, 43, 47, 48). NFAT is
also implicated in the regulation of expression of the cell sur-
face molecules Fas ligand and CD40 ligand (25, 50).
NFAT activation requires signals that are initiated by Ca21
and protein kinase C (PKC) (38). Activators of PKC, such as
phorbol 12-myristate 13-acetate (PMA), induce the synthesis
of the nuclear component (e.g., Fos and Jun family proteins).
A sustained increase in intracellular Ca21 is required to acti-
vate calcineurin, a Ca21-dependent phosphatase (49). Cal-
cineurin dephosphorylates NFAT proteins and induces their
translocation from the cytoplasm to the nucleus (9). The im-
munosuppressive drugs cyclosporin A and FK506 inhibit cal-
cineurin and, thereby, nuclear translocation of NFAT (14, 37).
Nuclear NFAT binds to specific DNA elements and activates
transcription. These processes are mediated, in part, by the
interaction of NFAT with AP-1 proteins. Some NFAT iso-
forms may also interact with other transcription factors, includ-
ing GATA-4 (30).
In T cells, NFAT is activated by the engagement of the
antigen-specific T-cell receptor (44). NFAT activity can also be
induced in other cell types in response to extracellular stimu-
lation. For example, ligation of surface immunoglobulins or
CD40 receptors in combination with IL-4 causes NFAT acti-
vation in B cells (20). Stimulation of NK cells by CD16 ligands
also causes NFAT activation (1). However, although NFAT is
activated in response to these stimuli, the contribution of
NFAT-mediated transcription to the expression of cytokine
genes and the specific role of NFAT in the immune response
remains unclear.
Recent studies designed to examine the role of the NFAT
transcription factor have used homologous recombination to
prepare mice that are defective in NFAT expression. Mice that
are deficient in the expression of NFAT1 and NFAT2 have
been reported (18, 24, 35, 41, 51, 53). NFAT1-deficient mice
show increased proliferation and dysregulation of IL-4 gene
expression (18, 24, 51). In contrast, IL-2 gene expression was
not affected in these mice. More recently, it has been reported
that mice deficient in NFAT2 show reduced IL-4 production
but normal or increased IL-2 secretion (35, 53). These data do
not provide evidence for a clear role of NFAT in the regulation
of IL-2 gene expression. The potential redundancy of NFAT
isoforms and the possible compensation by other NFAT iso-
forms in these knockout mice complicates the interpretation of
the phenotypes that have been reported.
The purpose of this study was to examine the role of NFAT
in the expression of IL-2. Since IL-2 expression is either unaf-
fected or enhanced in mice without NFAT1 or NFAT2, we used
a different approach to test whether NFAT activity is required
for IL-2 gene expression. We report the construction of a
mutated NFAT protein that dominantly inhibits NFAT func-
tion in vivo. This dominant-negative NFAT protein (dnNFAT)
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acts as a strong inhibitor of IL-2 expression. Thus, NFAT
activity is required for IL-2 expression.
MATERIALS AND METHODS
Cell culture and reagents. BHK fibroblasts, Jurkat T cells, and COS cells were
cultured in minimal essential medium, RPMI 1640, and Dulbecco modified
Eagle medium, respectively, supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U of penicillin per ml, and 100 mg of streptomycin per ml (Life
Technologies Inc.). Ionomycin and PMA were obtained from Sigma.
Plasmids. Mammalian expression vectors for NFAT and luciferase reporter
plasmids (NFAT and IL-2 promoter) were provided by T. Hoey (19). The green
fluorescence protein (GFP) expression vector pCMV-GFP was provided by D.
Kerr (University of Vermont). The calcineurin expression vector was obtained
from T. Soderling (32). The GAL4-luciferase, AP-1–luciferase, NF-kB–lucif-
erase, and pRSV b-galactosidase reporter plasmids and the expression vectors
for Flag-tagged NFAT and GAL4-NFAT have been described previously (7, 33,
39). The Rel homology domain of NFAT4 (NFAT4 Rel; amino acids 365 to 708)
was subcloned with an NH2-terminal hemagglutinin epitope tag in the expression
vector pCDNA3 (Invitrogen Inc.). Deletion and point mutations were con-
structed by PCR and sequenced with an Applied Biosystems machine.
Luciferase reporter gene assays. BHK cells were transfected by using Lipo-
fectamine as specified by the manufacturer (Life Technologies Inc.). A full-
length NFAT expression vector (0.3 mg) was cotransfected with the NFAT-
luciferase reporter plasmid (0.2 mg) and the pRSV b-galactosidase control
plasmid (0.2 mg). Various amounts (0.1 to 0.3 mg) of expression vectors for
NFAT deletion mutants were cotransfected. Jurkat T cells (5 3 106) were
transfected by electroporation (1,080 mF and 250 V; Life Technologies Inc.).
Luciferase reporter plasmids (5 mg) and the pRSV b-galactosidase control plas-
mid (5 mg) were cotransfected together with an NFAT expression vector (1 to 10
mg). The total amount of DNA was adjusted to 20 mg with plasmid pCDNA3.
Luciferase activity was measured 48 h after transfection. Unless otherwise indi-
cated, cells were stimulated with 2 mM ionomycin and 100 nM PMA for 16 h
prior to harvesting. The data are presented as luciferase activity/b-galactosidase
activity (mean 6 standard deviation SD [n 5 3]).
Immunoblot analysis. COS cells were transfected with NFAT expression vec-
tors by the Lipofectamine method (Life Technologies Inc.). The cells were
harvested in Triton-lysis buffer (20 mM Tris [pH 7.4], 137 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 25 mM b-glycerophosphate, 1 mM sodium vanadate,
2 mM sodium pyrophosphate, 10% glycerol, 1 mM phenylmethylsulfonyl fluo-
ride, 10 mg of leupeptin per ml) 48 h after transfection. Cell extracts were
separated by sodium dodecyl sulfate–12% polyacrylamide gel electrophoresis
and transferred to a polyvinylidene difluoride membrane (Millipore Inc.). The
epitope-tagged NFAT proteins were detected with a monoclonal antibody
(MAb) to Flag (Sigma) and enhanced chemiluminescence (Kirkegaard & Perry
Laboratories).
Immunofluorescence analysis. Transfected BHK cells were treated without
and with ionomycin (30 min) prior to fixation. Immunofluorescence analysis was
performed as described elsewhere (7). NFAT1 was detected with a rabbit poly-
clonal antibody (1:200; Upstate Biotechnology), and NFAT2 was detected with
a mouse MAb (1:200; Affinity Bioreagents). The secondary antibody was either
Texas red-conjugated anti-mouse or anti-rabbit immunoglobulin antibody (1:
100; Jackson Immunoresearch). Nuclei were visualized with 4,6-diamidino-2-
phenylindole (DAPI; Sigma).
IL-2 expression assays. Jurkat T cells (5 3 106) were transfected with expres-
sion vectors for NFAT (20 mg) and GFP (5 mg). GFP-positive and GFP-negative
cells were selected by cell sorting (Becton Dickinson) and treated without or with
ionomycin (2 mM) and PMA (100 nM) for 20 h. Culture supernatants were
collected and IL-2 was assayed with CTL.L cells as described previously (15).
Intracellular staining for IL-2 was performed with reagents from Pharmingen
Inc. according to the manufacturer’s protocol. Jurkat T cells were transfected
with expression vectors for NFAT and GFP. These cells were incubated for 20 h
without and with PMA and ionomycin. Four hours prior to harvesting, the cells
were incubated with monensin (2 mM) and subsequently fixed with paraformal-
dehyde (4%). Rat preimmune antibody (1 mg/ml) was used to block nonspecific
binding. Phycoerythrin-conjugated rat anti-human IL-2 antibody was used for
staining. The fluorescence intensity of GFP and phycoerythrin was measured by
flow cytometry (Becton Dickinson).
Mice. The DNA fragment encoding Flag-tagged dnNFAT (NFAT3 amino
acids 1 to 130) was subcloned downstream of the proximal lck promoter, and
transgenic mice were generated as described previously (39). Three expressing
positive founders lines were established and backcrossed onto B10.BR/SGSNJ
mice (The Jackson Laboratory). Thymocytes isolated from transgenic mouse
lines 4 and 8 were used for further studies. Expression of dnNFAT was confirmed
by immunoblot analysis of thymocyte lysates using MAb M2, specific to the Flag
epitope. After 24 h of activation, IL-2 production by these thymocytes (2 3 106
cells/ml) was determined by the CTL.L assay (15).
RESULTS
Construction of dnNFAT. Functional studies have identified
a transcription activation domain (TAD) in the NH2-terminal
region of NFAT (26). Adjacent to the TAD is a conserved
NFAT homology region that is similar in all members of the
NFAT group of transcription factors (17, 19, 27). This homol-
ogy region is highly phosphorylated and includes the sites of
regulatory phosphorylation that are substrates for the phos-
phatase calcineurin (38). The COOH-terminal region of
NFAT proteins includes a Rel homology domain which medi-
ates DNA binding (21). Studies of other transcription factors
indicate that the DNA binding domain can act as a dominant-
negative inhibitor by competition for DNA binding (5). This
approach to create a dominant-negative transcription factor
has not been successful for NFAT (data not shown). The lack
of success is caused by the finding that the DNA binding Rel
homology domain of NFAT activates NFAT-dependent re-
porter gene expression (26). This may be accounted for, in
part, by the interaction of the Rel homology domain with AP-1
complexes. Indeed, structural analysis indicates that the Rel
homology domain of NFAT is sufficient for complex formation
with AP-1 on DNA (6, 54).
As the DNA binding domain of NFAT does not appear to
function as a dominant inhibitor of NFAT function, we exam-
ined whether the conserved NH2-terminal NFAT homology
domain could interfere with NFAT-mediated transcription.
These experiments were performed by expression of a trun-
cated protein encoding the NFAT homology domain of
NFAT3 (residues 1 to 450) in BHK cells (Fig. 1A). The tran-
scription activity of NFAT2 was measured in cotransfection
assays using an NFAT-luciferase reporter plasmid. This re-
porter plasmid contains three copies of an NFAT–AP-1 com-
posite element derived from the IL-2 promoter. Treatment
with PMA and ionomycin induced NFAT2 transcriptional ac-
tivity (Fig. 1B). In the absence of NFAT2, transcription activity
was not observed in either the absence or the presence of the
NH2-terminal NFAT homology domain (data not shown). In
contrast, expression of the NH2-terminal NFAT homology do-
main (residues 1 to 450) inhibited transcription mediated by
NFAT2 (Fig. 1B). These data indicated that the NH2-terminal
NFAT homology domain interferes with NFAT-mediated
transcription.
The conserved NH2-terminal NFAT homology domain is
formed by distinct subregions (Fig. 1A). These include the
Ser-rich region (SRR) and three conserved Ser-Pro repeats
(SP boxes A, B, and C). The SP boxes represent major sites of
interaction of NFAT with calcineurin in vitro (7), and sites of
NFAT phosphorylation in vivo have been identified in the
SRR (3, 7, 55). To test whether these conserved subregions
(SRR and SP boxes) are required for the inhibitory function of
the NFAT homology domain, we generated a series of trun-
cated NFAT proteins (Fig. 1A). Removal of the COOH-ter-
minal portion of the SP boxes (residues 365 to 450) did not
affect the inhibitory activity (Fig. 1B), nor did truncation at
residue 160, which deletes the SP boxes and the adjacent SRR
(Fig. 1B). These data indicate that neither the SRR nor the SP
boxes are required for the inhibitory activity of the NH2-ter-
minal NFAT homology region.
The region identified that confers inhibitory transcription
activity (residues 1 to 160) includes the TAD, the conserved
Pro-Xaa-Ile-Xaa-Ile-Thr (PxIxIT) box (residues 114 to 119),
and the Tyr-Arg-Glu (YRE) box (residues 155 to 157) (Fig.
1A). To examine the role of these conserved subregions, we
performed further deletion analysis. Truncation at residue 130
removes the YRE box but does not alter the inhibitory activity
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of the NH2-terminal NFAT homology region (Fig. 1C). In
contrast, truncation at residue 112, which deletes the PxIxIT
box, abolished the inhibitory activity (Fig. 1C). Control exper-
iments demonstrated that these truncated NFAT proteins
were expressed at similar levels (Fig. 1D). Thus, it appears that
the conserved PxIxIT box is required for the dominant-nega-
tive function of the NH2-terminal NFAT homology region. To
test this hypothesis, we replaced the conserved Pro, Ile, and
Thr residues in the PxIxIT motif with Ala residues (Fig. 1A,
AxAxAA). This mutation eliminated the inhibitory activity of
the NH2-terminal NFAT homology region (Fig. 1C). These
data indicate that the PxIxIT box mediates the dominant-neg-
ative action of the NH2-terminal NFAT homology region.
The PxIxIT box selectively inhibits NFAT transcription ac-
tivity. The NH2-terminal NFAT homology domain is con-
served in the four members of the NFAT group of transcrip-
tion factors (38). We therefore reasoned that the dominant-
negative action of the PxIxIT box may inhibit transcription
activity of all members of this group. To test this hypothesis, we
examined the transcription activity of NFAT1, NFAT2,
NFAT3, and NFAT4 in a cotransfection assay with an NFAT-
luciferase reporter gene (Fig. 2). Transcription activity medi-
ated by each of these NFAT proteins was inhibited by coex-
FIG. 1. The PxIxIT domain acts as a dominant inhibitor of NFAT transcrip-
tion activity. (A) Schematic representation of the NH2-terminal region of NFAT
transcription factors. The conserved SP boxes (A, B, and C), TAD, PxIxIT motif,
YRE motif, and SRR are indicated. Mutation of the PxIxIT motif by replace-
ment of the Pro, Ile, and Thr residues with Ala (AxAxAA) is indicated by a cross.
The deletion mutations correspond to the NFAT3 isoform. (B) Expression of the
NH2-terminal NFAT homology region inhibits NFAT-mediated transcription
activity. Various NFAT3 deletion mutants (residues 1 to 450, 1 to 365, and 1 to
160) were coexpressed with full-length NFAT2 and an NFAT-luciferase reporter
plasmid in BHK cells. Luciferase activity was measured in cultures incubated
without (Untreated) or with ionomycin (2 mM) and PMA (100 nM) (I1P). The
data are presented as fold activation compared to an untreated control. (C) The
PxIxIT motif is responsible for the dominant-negative activity of the NH2-ter-
minal NFAT homology region. The effects of NFAT3 deletion mutants (residues
1 to 160, 1 to 130, and 1 to 112) on NFAT2-mediated transcription activity were
examined by using an NFAT-luciferase reporter plasmid in BHK cells. The effect
of mutation of the PxIxIT motif by replacement of the Pro, Ile, and Thr residues
with Ala (AxAxAA) was investigated. Luciferase activity was measured in cul-
tures incubated without (Untreated) or with ionomycin (2 mM) and PMA (100
nM) (I1P). The data are presented as fold activation compared to an untreated
control. (D) Epitope-tagged Flag-NFAT3 proteins were expressed in COS cells,
and detected by protein immunoblotting of cell lysates with MAb M5, specific to
the Flag epitope (Sigma). Sizes are indicated in kilodaltons.
FIG. 2. dnNFAT inhibits transcription activity of all four NFAT isoforms.
NFAT proteins were expressed in BHK cells together with dnNFAT (NFAT3
amino acids 1 to 130). The effect of mutation of the PxIxIT motif by replacement
of the Pro, Ile, and Thr residues with Ala (AxAxAA) was investigated. Cotrans-
fection assays in BHK cells using an NFAT-luciferase reporter plasmid and
NFAT1 (A), NFAT2 (B), NFAT3 (C), and NFAT4 (D) were performed. Lucif-
erase activity was measured in cultures treated without (open bar) and with
(filled bar) PMA and ionomycin. The data are presented as fold activation
compared to an untreated control.
FIG. 3. AP-1 and NF-kB transcription activities are not inhibited by dnNFAT.
NFAT, AP-1, and NF-kB transcription activities were measured by using lucif-
erase reporter plasmids cotransfected in Jurkat T cells without (Control) and
with dnNFAT. Luciferase activity was measured in cultures incubated with iono-
mycin (2 mM) and PMA (100 nM). The data are presented as relative percentage
activity compared to a control without dnNFAT.
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FIG. 4. Mechanism of dominant inhibitory activity of dnNFAT. (A) Transcription activity mediated by the COOH-terminal region of NFAT is not affected by
dnNFAT. Full-length NFAT4 and the NFAT4 COOH-terminal region (NFAT4 Rel; residues 365 to 708) were expressed together with an NFAT-luciferase reporter
plasmid in BHK cells without (Control) and with dnNFAT. Luciferase activity was measured in cultures incubated with ionomycin (2 mM) and PMA (100 nM). The
data are presented as relative percentage activity compared to a control without dnNFAT. (B) Transcription activity mediated by the NH2-terminal activation domain
of NFAT is not affected by dnNFAT. GAL4-NFAT4 fusion proteins were expressed in BHK cells together with a GAL4-luciferase reporter plasmid and dnNFAT.
Luciferase activity was measured in cultures incubated with ionomycin (2 mM) and PMA (100 nM). The data are presented as relative percentage activity compared
to a control without dnNFAT. The effect of replacement of the phosphorylation sites Ser-163 and Ser-165 with Ala is shown. DBD, DNA binding domain. (C)
Regulation of the subcellular distribution of NFAT proteins by dnNFAT. NFAT1 and NFAT2 were coexpressed with dnNFAT in BHK cells. Immunofluorescence
analysis was performed on cells treated without or with ionomycin (2 mM, 30 min). NFAT proteins (red) and the nucleus (blue) were visualized. Arrowheads indicate
the nuclei of cells expressing transfected proteins. (D) Overexpression of calcineurin opposed the inhibitory effect of dnNFAT. Various amounts of calcineurin
expression vector (50 and 100 ng) were coexpressed with dnNFAT in BHK cells. Immunofluorescence analysis was performed to examine the subcellular distribution
of NFAT1 and NFAT2 proteins in the absence or presence of ionomycin (2 mM, 30 min). One hundred transfected cells were examined. The percentage of cells with
NFAT in the nucleus is presented.
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pression with the PxIxIT box (NFAT3 residues 1 to 130). In
contrast, expression of the Ala-substituted PxIxIT box did not
inhibit transcription activity. These data indicate that the Px-
IxIT box can function as a dominant-negative NFAT mutant
that suppresses transcription mediated by NFAT transcription
factors.
It was possible that dnNFAT could inhibit transcription ac-
tivity nonspecifically. We therefore examined the effect of
dnNFAT on transcription activity mediated by AP-1 and NF-
kB. dnNFAT did not inhibit AP-1- or NF-kB-dependent re-
porter gene expression in cotransfection assays but did cause
selective inhibition of NFAT transcription activity (Fig. 3).
Mechanism of the inhibitory activity of dnNFAT. Previous
studies indicated that both the NH2- and COOH-terminal re-
gions of NFAT proteins can mediate transcription activity (26).
The NH2-terminal region of NFAT acts as a strong transacti-
vation domain (Fig. 1A). In addition, the COOH-terminal
region, which includes the Rel homology domain, can also
mediate transactivation which may be caused, in part, by the
association of the NFAT Rel domain with other transcription
factors, such as AP-1 (4, 23, 52). To gain insight into the
mechanism by which dnNFAT inhibits NFAT transcription
activity, we examined the effect of dnNFAT on the transcrip-
tion activity mediated by the NH2- and COOH-terminal re-
gions of NFAT. Interestingly, while dnNFAT did inhibit tran-
scription activity of full-length NFAT, no significant inhibition
of transcription activity mediated by the COOH-terminal re-
gion of NFAT was detected (Fig. 4A). The absence of an effect
of dnNFAT on transcription mediated by the COOH-terminal
region of NFAT suggests that the inhibition of NFAT tran-
scription activity requires the NH2-terminal NFAT homology
domain. To test this hypothesis, we fused the NH2-terminal
region of NFAT4 (residues 1 to 207) to the GAL4 DNA
binding domain and examined the effect of dnNFAT on tran-
scription activation in cotransfection assays with a GAL4-lu-
ciferase reporter plasmid. dnNFAT was found to inhibit the
transcription activity of this GAL4-NFAT4 fusion protein (Fig.
4B). These data indicate that the NH2-terminal region of
NFAT is both necessary and sufficient for the response of the
NFAT transcription factor to the inhibitory action of dnNFAT.
It was possible that dnNFAT interferes with the mechanism
of transcription activation mediated by NFAT. However, the
results of deletion analysis of the NFAT4 NH2-terminal region
in the GAL4 fusion protein assay did not support this hypoth-
esis (Fig. 4B). While dnNFAT inhibited the transcription ac-
tivity of GAL4-NFAT4 (residues 1 to 207), dnNFAT did not
inhibit transcription activity of GAL4-NFAT4 (residues 1 to
146). Since NFAT4 residues 1 to 146 include the NH2-terminal
TAD, the absence of inhibition by dnNFAT demonstrates that
dnNFAT does not act by directly interfering with transcription
activation.
It appears that the inhibitory effect of dnNFAT is not me-
diated by direct inhibition of transcription activation (Fig. 4B)
and is not mediated by regulation of the Rel homology region
that binds DNA (Fig. 4A). However, residues 146 to 207 of the
NH2-terminal homology region of the target NFAT molecule
are required for inhibition by dnNFAT (Fig. 4B). Since this
region contributes to the regulated nuclear translocation of
NFAT (3, 7), we tested the effect of dnNFAT on Ca21-stim-
ulated nuclear accumulation of NFAT proteins. Immunofluo-
rescence analysis indicated that NFAT1 is located in the cy-
tosol of unstimulated cells (Fig. 4C). Upon treatment with
ionomycin, NFAT1 translocates into the nucleus (Fig. 4C).
However, the ionomycin-induced nuclear translocation of
NFAT1 was blocked by the expression of dnNFAT (Fig. 4C).
Similar inhibitory effects on nuclear translocation of NFAT2
caused by the expression of dnNFAT was observed (Fig. 4C).
These data indicate that Ca21-stimulated nuclear translocation
of NFAT transcription factors is inhibited by dnNFAT. This
conclusion is consistent with the observation that dnNFAT did
not inhibit the transcriptional activity of constitutively nuclear
GAL4-NFAT4 (Ala-163, Ala-165) (Fig. 4B).
Previous studies indicated that nuclear translocation of
NFAT is mediated, in part, by calcineurin upon sustained in-
crease in intracellular calcium (45, 49). Since dnNFAT blocks
nuclear translocation of NFAT, we tested whether overexpres-
sion of calcineurin in cells would oppose the inhibitory effect by
dnNFAT. We performed immunofluorescence analysis and ex-
amined the subcellular distribution of NFAT proteins. Expres-
sion of calcineurin did not affect the subcellular distribution of
the NFAT proteins in the presence or absence of ionomycin
(Fig. 4D). Expression of dnNFAT caused decreased nuclear
accumulation of NFAT proteins (Fig. 4D). Overexpression of
calcineurin, however, opposed the inhibitory effect of dnNFAT
and increased nuclear accumulation of NFAT proteins (Fig.
4D). These data indicate that dnNFAT blocks nuclear trans-
location of NFAT proteins by interfering with calcineurin.
IL-2 expression is inhibited by dnNFAT. NFAT was initially
characterized as a nuclear transcription factor of activated T
cells that binds to the IL-2 promoter (13). However, the con-
tribution of NFAT-mediated transcription to IL-2 expression
remains unclear. Recent studies demonstrate that IL-2 produc-
tion is not decreased in mice lacking NFAT1 or NFAT2 (18,
24, 36, 41, 51, 53). These data may indicate that NFAT is not
relevant to IL-2 expression, that the functions of NFAT iso-
forms are redundant, or that there are compensatory changes
in the expression of other NFAT family members in NFAT-
deficient mice. The role of NFAT in IL-2 expression therefore
remains to be established. To test the involvement of NFAT in
IL-2 expression, we examined the effect of dnNFAT.
We examined whether dnNFAT inhibited the endogenous
NFAT activity in Jurkat T cells in a transfection experiment
using an NFAT-luciferase reporter plasmid (Fig. 5). Expres-
sion of dnNFAT caused a dose-dependent inhibition of NFAT
transcription activity. This inhibition was blocked by the re-
placement of the conserved Pro, Ile, and Thr residues in the
PxIxIT motif with Ala residues. Similar studies were per-
FIG. 5. dnNFAT causes a dose-dependent inhibition of NFAT activity in
Jurkat T cells. Increasing amounts (1, 3, 6, and 9 mg) of a dnNFAT expression
vector were transfected in Jurkat T cells. The transcription activity of endoge-
nous NFAT was detected with an NFAT-luciferase reporter plasmid. The effect
of mutation of the PxIxIT motif by replacement of the Pro, Ile, and Thr residues
with Ala (AxAxAA) was investigated. Luciferase activity was measured in cul-
tures incubated without (2) or with (1) ionomycin (2 mM) and PMA (100 nM)
(I1P). The data are presented as fold activation compared to an untreated
control.
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formed with a luciferase reporter plasmid under the control of
the IL-2 promoter (Fig. 6A). The dnNFAT (PxIxIT), but not
the Ala-substituted mutant (AxAxAA), caused inhibition of
IL-2 promoter activity in Jurkat T cells. The inhibition of IL-2
promoter activity caused by dnNFAT was similar to that
caused by mutation of an NFAT binding site in the IL-2 pro-
moter (13). These data indicate that NFAT transcription ac-
tivity is required for IL-2 gene expression.
To confirm the results obtained with the IL-2 promoter
reporter plasmid, we examined the effect of dnNFAT on IL-2
secretion. Jurkat T cells were cotransfected with expression
vectors for GFP and dnNFAT. The transfected cells were
selected by cell sorting and treated with PMA and ionomycin
(Fig. 6B). Cells transfected with GFP alone demonstrated a
large increase in IL-2 secretion following treatment with PMA
and ionomycin. In contrast, IL-2 secretion was markedly re-
duced in cells cotransfected with GFP and dnNFAT. The abil-
ity of dnNFAT to reduce IL-2 secretion was eliminated if the
conserved residues in the PxIxIT motif were replaced with Ala.
These data indicate that dnNFAT inhibits IL-2 production in
vivo.
To further confirm that IL-2 production is inhibited by dnN-
FAT, we directly measured the amount of IL-2 expressed by
individual Jurkat T cells by the intracellular cytokine staining
procedure (Fig. 6C). Jurkat T cells were transfected with GFP
alone, GFP plus dnNFAT (PxIxIT), and GFP plus the mutated
dnNFAT (AxAxAA). These cultures were treated without and
with PMA plus ionomycin and then examined by flow cytomet-
ric analysis of GFP and IL-2. Treatment with PMA plus iono-
mycin caused similar increases in IL-2 detected in the untrans-
fected (GFP-negative) cells present in each culture. Increased
amounts of IL-2 were also detected in the transfected (GFP-
positive) cells. Expression of dnNFAT caused a large decrease
in IL-2 accumulation. In contrast, the mutated dnNFAT (Ax-
AxAA) caused no change in IL-2 accumulation. These data
indicate that dnNFAT inhibits expression of IL-2.
To test the effect of dnNFAT in IL-2 production in primary
cells, we generated transgenic mice that express dnNFAT in
the thymus using the proximal lck promoter. Immunoblot anal-
ysis showed the expression of dnNFAT in the thymus of the
positive transgenic mice (Fig. 6D). We isolated thymocytes
from control littermates and dnNFAT transgenic mice and
measured IL-2 production in response to PMA plus ionomy-
cin. We found that the production of IL-2 was markedly re-
duced in thymocytes from two different dnNFAT transgenic
mouse lines than in those from the negative littermate control
mice (Fig. 6D). Together, these data demonstrate that dnN-
FAT inhibits IL-2 expression not only in a T-cell clone (e.g.,
Jurkat cells) but also in primary cells. These data therefore
provide strong support for the conclusion that NFAT is criti-
cally important for IL-2 gene expression.
DISCUSSION
Disruption of the NFAT1 gene in mice has been reported
to cause enhanced immune responses (18, 24, 41, 51). The
molecular basis for this effect of NFAT1 gene disruption is
unclear. The levels of production of IL-2, IL-4, tumor necrosis
FIG. 6. dnNFAT inhibits IL-2 production. (A) The activity of the IL-2 pro-
moter is inhibited by dnNFAT. Jurkat T cells were cotransfected with an IL-2
promoter-luciferase reporter plasmid and various amounts (1 and 10 mg) of
dnNFAT expression vector. The effect of mutation of the PxIxIT motif by
replacement of the Pro, Ile, and Thr residues with Ala (AxAxAA) was investi-
gated. Luciferase activity was measured in cultures incubated without (2) or with
(1) ionomycin (2 mM) and PMA (100 nM) (I1P). The data are presented as fold
activation compared to an untreated control. (B) IL-2 secretion is inhibited by
dnNFAT. Jurkat T cells were cotransfected with expression vectors for GFP and
dnNFAT (either wild-type PxIxIT or mutated AxAxAA). Transfected cells ex-
pressing GFP were selected by flow cytometry and treated without (Untreated)
or with ionomycin (2 mM) and PMA (100 nM) (I1P), and the amount of IL-2
secreted in the culture medium was measured. (C) IL-2 expression is inhibited by
dnNFAT. Jurkat T cells were cotransfected without (Control) and with expres-
sion vectors for GFP and dnNFAT (either wild-type PxIxIT or mutated Ax-
AxAA). The cells were treated without (thin line) or with (thick line) ionomycin
(2 mM) and PMA (100 nM) (I1P). The intracellular IL-2 and GFP was mea-
sured by flow cytometry. IL-2 expression (mean fluorescence intensity) of the
transfected GFP positive (1) and untransfected GFP negative (2) cells in each
culture is shown. (D) Thymocytes from dnNFAT transgenic mice have reduced
IL-2 expression. Thymocytes were isolated from dnNFAT transgenic mice (Tg1)
and control nontransgenic littermates (NLC). Expression of dnNFAT was de-
tected by protein immunoblot analysis using MAb M2, specific to the Flag
epitope. Cells were stimulated with ionomycin (2 mM) and PMA (100 nM), and
the amount of IL-2 secreted in the culture medium was measured. hGH, human
growth hormone.
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factor alpha, and gamma interferon by wild-type and
NFAT12/2 T cells in response to anti-CD3 MAb or con-
canavalin A are similar (51). In contrast, NFAT12/2 T cells
expressed reduced amounts of IL-4 when treated with con-
canavalin A in vitro (41). A similar decrease in IL-4 expression
was reported in response to the administration of anti-CD3
MAb in vivo, but Th2 cell development and late IL-4 produc-
tion in vitro were enhanced (18). In a separate study, no dif-
ferences in early IL-4 gene expression were detected, but the
expression of IL-4 was more sustained in NFAT12/2 mice (24).
None of these reports demonstrate changes in the expression
of IL-2, suggesting either that NFAT1 is not required for IL-2
gene expression or that other members of the NFAT family
can compensate for the absence of NFAT1 in these mice.
Mice deficient in the expression of NFAT2 have also been
reported (36, 53). Disruption of the NFAT2 gene causes early
embryonic death due to impairment of heart development (11,
35). However, the creation of Rag22/2 NFAT22/2 chimeric
mice has enabled studies of immune responses. These studies
have demonstrated that NFAT2 gene disruption causes im-
paired Th2 responses with reduced IL-4 production (36, 53).
However, the effect on IL-2 production is unclear. The study by
Ranger et al. shows increased IL-2 production (36). In con-
trast, Yoshida et al. detected no differences in IL-2 expression
in NFAT2-deficient mice (53). The interpretation of these data
is confounded by the observation that disruption of the NFAT2
gene alters the development of T cells in the thymus. Thus, it
is possible that the population of T cells present in the spleen
or lymph nodes of the Rag22/2 NFAT22/2 chimeric mice does
not represent normal T cells.
The failure of the reported gene disruption studies to dem-
onstrate a role for NFAT in IL-2 gene expression may result
from functional redundancy or compensatory changes in the
knockout mice. It is therefore possible that NFAT contributes
to the expression of IL-2 in T cells. Indeed, several lines of
evidence that support the contention that NFAT contributes to
the regulation of IL-2 gene expression have been reported.
First, NFAT binding sites are located in the IL-2 promoter
(44). Second, mutational analysis of the distal NFAT binding
site present in the IL-2 promoter demonstrates that this DNA
element contributes to IL-2 gene expression (13). Third,
NFAT activation correlates with IL-2 secretion (22, 44).
Fourth, immunosuppressive drugs (e.g., cyclosporin A and
FK506) which reduce calcineurin activity inhibit both NFAT-
mediated transcription and IL-2 gene expression (14, 16, 34).
Together, these data provide strong support for the hypothesis
that NFAT contributes to IL-2 secretion. However, the re-
quirement of NFAT binding sites and calcineurin activity for
IL-2 expression does not establish that NFAT is necessary for
this process. Further studies are therefore required to demon-
strate a role for NFAT in IL-2 gene expression.
We have tested the involvement of NFAT in IL-2 expression
by using the dnNFAT molecule. The active component of this
inhibitor corresponds to the PxIxIT box located in the con-
served NH2-terminal homology region of NFAT (Fig. 1).
dnNFAT selectively inhibited NFAT transcription activity by
interfering with the activation-induced nuclear import of
NFAT. These data suggest that the normal function of the
PxIxIT box in NFAT contributes to nuclear accumulation. In-
deed, deletion of the PxIxIT box inhibits activation-induced
nuclear import of NFAT (2, 55). The mechanism of action of
dnNFAT is likely to be mediated by interference with the
normal function of the conserved PxIxIT box. This function
may involve the targeting of NFAT to calcineurin, which is
required for NFAT activation. Interestingly, overexpression of
calcineurin opposed the inhibitory effect mediated by the Px-
IxIT box (dnNFAT) (Fig. 4D). In addition, in vitro studies
demonstrate that peptides corresponding to the PxIxIT box
inhibit the dephosphorylation of NFAT by calcineurin (2). This
effect of the PxIxIT peptide is not mediated by inhibition of
calcineurin activity. Instead, the PxIxIT peptide prevents the
recognition of NFAT as a substrate by calcineurin without
altering the ability of calcineurin to dephosphorylate other
substrates (2). Thus, in contrast to the immunosuppressive
drugs cyclosporin A and FK506, which cause inhibition of all
calcineurin signaling functions, the PxIxIT box is a selective
inhibitor of NFAT dephosphorylation in vitro. In this study, we
demonstrate that expression of the PxIxIT box (dnNFAT) in T
cells causes selective inhibition of NFAT transcription activity.
We have used dnNFAT to test the role of NFAT in IL-2
gene expression. Inhibition of NFAT-mediated transcription
by dnNFAT resulted in dose-dependent inhibition of IL-2 pro-
moter activity in Jurkat T cells. These data indicate that the
NFAT transcription factor is required for normal expression of
the IL-2 gene. Moreover, we have shown that IL-2 secretion is
markedly inhibited by dnNFAT (Fig. 6). More importantly, we
have demonstrated that dnNFAT inhibited IL-2 production in
a transgenic animal model (Fig. 6D). Together, our results
demonstrate that dnNFAT inhibits the production of IL-2.
Thus, the NFAT transcription factor contributes to the regu-
lation of IL-2 gene expression and therefore plays a critical
role in the initiation of immune responses.
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